CYTOMEGALOVIRUS CELL-MEDIATED IMMUNITY GUIDED LETERMOVIR PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL (EBMT 2026) - Feb 7, 2026 - Abstract #OS09-01; Pres time: Mar 24, 2026; 09:00 AM - 09:09 AM; Location: N104; P3 | "Letermovir was given orally or intravenously at a dose of 480 mg daily from day 1, or 240 mg daily when in conjunction with cyclosporine A. CMV-CMI was evaluated with CMV-ELISPOT at at the 3rd, 5th, 6th, and 9th month post-HCT. The CMV-CMI-guided strategy of letermovir use for CMV prophylaxis after allo-HCT is effective and safe in reducing the cumulative incidence of late-onset cs-CMVi after letermovir withdrawal."
Clinical • P3 data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
Luxiang Wang1; Yang Yang2; Tingting Han3; Yi Yu4; Chuanhe Jiang1; Jiayu Huang1; Haiyang Lu1; Su Li5; Shilin Gan6; Chen Chen6; Hai Yi7; Lijing Shen8; Xinfeng Wang9; Yanmin Zhao4; Xiaodong Mo10; Yang Cao2; Xiaoxia Hu1
|